loading
Precedente Chiudi:
$6.32
Aprire:
$6.32
Volume 24 ore:
636.70K
Relative Volume:
0.45
Capitalizzazione di mercato:
$283.13M
Reddito:
$217.25M
Utile/perdita netta:
$-50.92M
Rapporto P/E:
-6.435
EPS:
-1
Flusso di cassa netto:
$-100.85M
1 W Prestazione:
+4.13%
1M Prestazione:
+33.23%
6M Prestazione:
-53.60%
1 anno Prestazione:
-67.94%
Intervallo 1D:
Value
$6.21
$6.4564
Intervallo di 1 settimana:
Value
$5.96
$6.585
Portata 52W:
Value
$4.32
$25.42

Prothena Corporation Plc Stock (PRTA) Company Profile

Name
Nome
Prothena Corporation Plc
Name
Telefono
011-353-1-236-2500
Name
Indirizzo
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Name
Dipendente
163
Name
Cinguettio
@ProthenaCorp
Name
Prossima data di guadagno
2025-02-18
Name
Ultimi documenti SEC
Name
PRTA's Discussions on Twitter

Confronta PRTA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PRTA
Prothena Corporation Plc
6.435 283.13M 217.25M -50.92M -100.85M -1.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-28 Downgrade BofA Securities Neutral → Underperform
2025-05-27 Downgrade Cantor Fitzgerald Overweight → Neutral
2025-05-27 Downgrade Jefferies Buy → Hold
2025-05-27 Downgrade Oppenheimer Outperform → Perform
2024-12-20 Iniziato Chardan Capital Markets Buy
2024-01-30 Downgrade BofA Securities Buy → Neutral
2023-12-12 Iniziato Deutsche Bank Buy
2023-04-24 Iniziato SVB Securities Outperform
2023-01-27 Iniziato Piper Sandler Overweight
2022-11-04 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-09-28 Aggiornamento BofA Securities Neutral → Buy
2021-11-19 Iniziato JMP Securities Mkt Outperform
2021-06-18 Aggiornamento BofA Securities Underperform → Neutral
2021-06-08 Reiterato Oppenheimer Outperform
2021-05-26 Iniziato Citigroup Buy
2021-02-26 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2021-02-12 Aggiornamento Jefferies Hold → Buy
2021-02-02 Aggiornamento BTIG Research Neutral → Buy
2020-12-07 Iniziato H.C. Wainwright Buy
2020-07-09 Aggiornamento Oppenheimer Perform → Outperform
2019-11-19 Aggiornamento Evercore ISI In-line → Outperform
2018-05-21 Downgrade Barclays Equal Weight → Underweight
2018-04-23 Downgrade Jefferies Buy → Hold
2018-04-05 Reiterato Barclays Overweight
2017-11-20 Downgrade Wedbush Outperform → Neutral
2017-09-29 Reiterato BTIG Research Buy
2017-09-15 Iniziato RBC Capital Mkts Outperform
2017-08-17 Iniziato Evercore ISI Outperform
2017-07-11 Iniziato Jefferies Buy
2017-04-12 Iniziato Cantor Fitzgerald Overweight
2017-04-12 Iniziato Piper Jaffray Overweight
2017-03-02 Iniziato Instinet Buy
2016-12-21 Iniziato SunTrust Buy
2016-11-03 Iniziato Deutsche Bank Buy
2016-08-04 Reiterato Barclays Overweight
2016-05-13 Iniziato Barclays Overweight
2016-02-19 Reiterato Wedbush Outperform
2016-01-21 Iniziato Credit Suisse Outperform
Mostra tutto

Prothena Corporation Plc Borsa (PRTA) Ultime notizie

pulisher
Jun 18, 2025

Prothena announces 63% workforce reduction following birtamimab halt - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (PRTA) Cuts Workforce by 63% to Reduce Costs - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (PRTA) Shares Rise Following Corporate Restructuring an - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena Announces Major Workforce Reduction to Cut Costs - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (PRTA) Adjusts 2025 Financial Outlook Amid Reorganizati - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena Announces Corporate Restructuring | PRTA Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (PRTA) Announces Leadership Changes Amid Workforce Reduction | PRTA Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena to cut workforce by 63% amid strategic review - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena announces corporate restructuring - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena Announces Corporate Restructuring - Business Wire

Jun 18, 2025
pulisher
Jun 18, 2025

Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Prothena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average – Time to Sell? - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) - Insider Monkey

Jun 17, 2025
pulisher
Jun 16, 2025

(PRTA) Trading Signals - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Financial Analysis: Prothena Corporation plc (PRTA)’s Ratios Unveil Key Insights - DWinneX

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena stock rises on Parkinson's trial update (PRTA:NASDAQ) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena’s Prasinezumab Advances to Phase III for Parkinson’s - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena partner Roche advances Parkinson’s drug to phase 3 By Investing.com - Investing.com Nigeria

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Prothena's Partner Roche to Advance Prasinezumab into Phase III - GuruFocus

Jun 16, 2025
pulisher
Jun 14, 2025

Prothena’s SWOT analysis: stock faces challenges after trial setback By Investing.com - Investing.com South Africa

Jun 14, 2025
pulisher
Jun 14, 2025

Prothena’s SWOT analysis: stock faces challenges after trial setback - Investing.com

Jun 14, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts Prothena FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Two Sigma Investments LP Buys 27,887 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Prothena Co. plc (NASDAQ:PRTA) Short Interest Update - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Bank of America Corp DE Purchases 36,944 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

(PRTA) Technical Data - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 03, 2025

Millennium Management LLC Has $1.70 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

PROTHENA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Prothena Corporation plc To Contact The Firm - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 02, 2025

ProShare Advisors LLC Buys 3,312 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World

Jun 02, 2025
pulisher
May 31, 2025

Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN

May 31, 2025
pulisher
May 31, 2025

Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

May 31, 2025
pulisher
May 31, 2025

Chardan Capital Decreases Earnings Estimates for Prothena - Defense World

May 31, 2025
pulisher
May 30, 2025

Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails - MSN

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PT - Insider Monkey

May 30, 2025
pulisher
May 30, 2025

FY2027 EPS Estimates for Prothena Decreased by HC Wainwright - Defense World

May 30, 2025
pulisher
May 30, 2025

Prothena (NASDAQ:PRTA) Given “Underperform” Rating at Bank of America - Defense World

May 30, 2025
pulisher
May 29, 2025

Bank of America Reiterates “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World

May 29, 2025
pulisher
May 29, 2025

Bank of America Reaffirms “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World

May 29, 2025
pulisher
May 29, 2025

Prothena (NASDAQ:PRTA) Receives Underperform Rating from Bank of America - Defense World

May 29, 2025
pulisher
May 29, 2025

The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st

May 29, 2025
pulisher
May 29, 2025

BofA cuts Prothena stock rating, slashes target to $4 By Investing.com - Investing.com Nigeria

May 29, 2025
pulisher
May 28, 2025

Prothena Corp (PRTA) Sees Downgrade and Price Target Cut by B of A Securities | PRTA Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform - Insider Monkey

May 28, 2025
pulisher
May 28, 2025

BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | P - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | PRTA Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down - MSN

May 28, 2025
pulisher
May 28, 2025

Prothena (PRTA) Downgraded by BofA Analyst with Lower Price Targ - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Prothena (NASDAQ:PRTA) Price Target Lowered to $81.00 at Piper Sandler - Defense World

May 28, 2025

Prothena Corporation Plc Azioni (PRTA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Prothena Corporation Plc Azioni (PRTA) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
EcoR1 Capital, LLC
10% Owner
May 06 '25
Sale
7.64
1,984,053
15,164,712
5,304,596
EcoR1 Capital, LLC
10% Owner
May 05 '25
Sale
8.11
977,693
7,930,166
7,288,649
SCULLY WILLIAM P
10% Owner
Jan 14 '25
Buy
12.79
100,000
1,279,040
735,993
SCULLY WILLIAM P
10% Owner
Dec 18 '24
Buy
13.93
73,436
1,022,670
1,297,693
SCULLY WILLIAM P
10% Owner
Dec 31 '24
Buy
13.01
32,000
416,393
650,193
SCULLY WILLIAM P
10% Owner
Dec 20 '24
Buy
15.91
2,000
31,813
618,693
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Capitalizzazione:     |  Volume (24 ore):